日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

RETRACTED: Richards et al. Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC). Int. J. Mol. Sci. 2023, 24, 10545

撤稿:Richards 等人,《蛋白酪氨酸磷酸酶非受体 11 (PTPN11/Shp2) 作为非小细胞肺癌 (NSCLC) 的驱动癌基因和新型治疗靶点》,《国际分子科学杂志》,2023 年,24 卷,10545 页。

Richards, Cathy E; Elamin, Yasir Y; Carr, Aoife; Gately, Kathy; Rafee, Shereen; Cremona, Mattia; Hanrahan, Emer; Smyth, Robert; Ryan, Daniel; Morgan, Ross K; Kennedy, Susan; Hudson, Lance; Fay, Joanna; O'Byrne, Kenneth; Hennessy, Bryan T; Toomey, Sinead

Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo

奈拉替尼联合达沙替尼在体外和体内对HER2阳性乳腺癌具有高度协同作用。

Conlon, Neil T; Roche, Sandra; Mahdi, Amira F; Browne, Alacoque; Breen, Laura; Gaubatz, Johanna; Meiller, Justine; O'Neill, Fiona; O'Driscoll, Lorraine; Cremona, Mattia; Hennessy, Bryan T; Eli, Lisa D; Crown, John; Collins, Denis M

Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development.

乳腺癌细胞蛋白质组学时间进程显示,在内分泌耐药性发展之前,对 Stat3 和 Src 抑制剂的敏感性增强

Madden Stephen F, Cremona Mattia, Farrelly Angela M, Low Weng Hei, McBryan Jean

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer

CDK4/6抑制剂帕博西尼联合PI3K或MEK抑制剂治疗结直肠癌的临床前评估

Lee, Cha Len; Cremona, Mattia; Farrelly, Angela; Workman, Julie A; Kennedy, Sean; Aslam, Razia; Carr, Aoife; Madden, Stephen; O'Neill, Brian; Hennessy, Bryan T; Toomey, Sinead

Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples

实体瘤样本中潜在可靶向的体细胞致癌突变的鉴定及其临床影响

Toomey, Sinead; Carr, Aoife; Mezynski, Mateusz Janusz; Elamin, Yasir; Rafee, Shereen; Cremona, Mattia; Morgan, Clare; Madden, Stephen; Abdul-Jalil, Khairun I; Gately, Kathy; Farrelly, Angela; Kay, Elaine W; Kennedy, Susan; O'Byrne, Kenneth; Grogan, Liam; Breathnach, Oscar; Morris, Patrick G; Eustace, Alexander J; Fay, Joanna; Cummins, Robert; O'Grady, Anthony; Kalachand, Roshni; O'Donovan, Norma; Kelleher, Fergal; O'Reilly, Aine; Doherty, Mark; Crown, John; Hennessy, Bryan T

Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro.

体外子宫内膜癌中 PI3K 和 MEK 抑制剂的临床前评估和反相蛋白芯片分析

Aslan Ozlem, Cremona Mattia, Morgan Clare, Cheung Lydia W, Mills Gordon B, Hennessy Bryan T

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)

ERBB3 和 BARD1 基因的种系单核苷酸多态性导致接受多西他赛、卡铂和曲妥珠单抗 (TCH) 辅助治疗的 HER2 阳性乳腺癌患者的无复发生存期反应较差。

Coté, Damien; Eustace, Alex; Toomey, Sinead; Cremona, Mattia; Milewska, Malgorzata; Furney, Simon; Carr, Aoife; Fay, Joanna; Kay, Elaine; Kennedy, Susan; Crown, John; Hennessy, Bryan; Madden, Stephen

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer

ERBB家族种系单核苷酸多态性对HER2阳性乳腺癌患者接受曲妥珠单抗辅助治疗后生存反应的影响

Toomey, Sinead; Madden, Stephen F; Furney, Simon J; Fan, Yue; McCormack, Mark; Stapleton, Carragh; Cremona, Mattia; Cavalleri, Gianpiero L; Milewska, Malgorzata; Elster, Naomi; Carr, Aoife; Fay, Joanna; Kay, Elaine W; Kennedy, Susan; Crown, John; Gallagher, William M; Hennessy, Bryan T; Eustace, Alex J